Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics' stock has been impacted by several events in the past six months. The strategic pivot to OTC dermatology in September and November 2025 led to a stock price decline, with the stock losing approximately 50% since November 30, 2025. Share dilution occurred, with total shares outstanding increasing significantly. In December 2025, a private placement of up to $12.4 million was announced and closed. In January 2026, the company received a patent grant for an acne treatment. Corporate updates and financial results in March 2026 showed a net loss of $7.6 million for 2025. Kyra Peckaitis was appointed as Vice President, Marketing, and Tome Skincare was launched in March 2026. A reverse stock split with a ratio of 1:10 occurred on August 1, 2025.

Demand for Dermata Therapeutics' products may be influenced by seasonality, new product launches, product cycles, pricing, product defects, promotions, and shifts in consumer spending patterns. The company aims to maintain high service levels through reliable inventory planning and demand forecasting.

Dermata Therapeutics, Inc., established in 2014, is a clinical-stage biotechnology company focused on developing and commercializing products for skin diseases and aesthetic conditions. The company operates in the Healthcare sector, specifically in Biotechnology, Medical Research, and Pharmaceutical Products. Dermata has shifted its focus from prescription dermatology to over-the-counter (OTC) skincare treatments, utilizing its proprietary Spongilla platform technology. Key products include DMT310 (XYNGARI) for acne and psoriasis, DMT410 for topical delivery of large molecules, and the Tome Skincare line for direct-to-consumer OTC solutions.

Dermata Therapeutics, Inc. is headquartered in San Diego, California, United States. The company's focus on direct-to-consumer (DTC) and professional B2B channels for its Tome skincare line suggests a primary market within the United States.

Dermata Therapeutics' brand reputation has been shaped by its strategic shift to a direct-to-consumer and professional skincare strategy with the launch of its new Tome Skincare brand. This move aims to leverage its scientific credibility and innovative Spongilla technology to meet consumer demand for accessible and effective dermatologic solutions.

Dermata Therapeutics, Inc. has both institutional and individual owners. Major institutional owners include Clear Street Group Inc., Bank Of America Corp /de/, Barclays Plc, Tower Research Capital LLC (TRC), UBS Group AG, Jpmorgan Chase & Co, and SBI Securities Co., Ltd. Gerald T. Proehl, the Founder, President, CEO, and Chairman, beneficially owns 694,687 shares, representing 17.3% of the company's outstanding common stock.